Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929878 | 0.84 | TTR (0.38) | TTR | |
| SCHEMBL26334545 | 0.81 | — | — | |
| SCHEMBL6923611 | 0.78 | ALDH1A1 (0.36) | — | |
| SCHEMBL22089476 | 0.77 | CYP3A4 (0.39) | — | |
| SCHEMBL29971161 | 0.77 | CYP3A4 (0.39) | — | |
| SCHEMBL27129823 | 0.75 | GAA (0.32) | — | |
| SCHEMBL26341394 | 0.71 | ADRB2 (0.31) | — | |
| SCHEMBL26334549 | 0.70 | TTR (0.32) | TTR | |
| SCHEMBL28200847 | 0.70 | CA2 (0.40) | — | |
| SCHEMBL7969500 | 0.70 | HTR1D (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2023-10-19 | — | — | US | disclosed |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331745-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | TTR 186/4885 |
| US-11767332-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | TTR 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.